- Home
- ORIC vs COGT Comparison
ORIC vs COGT Comparison
Compare ORIC & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- COGT
- Stock Information
- Founded
- ORIC 2014
- COGT 2014
- Country
- ORIC United States
- COGT United States
- Employees
- ORIC N/A
- COGT N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- COGT Health Care
- Exchange
- ORIC Nasdaq
- COGT Nasdaq
- Market Cap
- ORIC 974.1M
- COGT 1.1B
- IPO Year
- ORIC 2020
- COGT 2018
- Fundamental
- Price
- ORIC $10.88
- COGT $13.05
- Analyst Decision
- ORIC Strong Buy
- COGT Strong Buy
- Analyst Count
- ORIC 10
- COGT 11
- Target Price
- ORIC $17.33
- COGT $21.20
- AVG Volume (30 Days)
- ORIC 782.2K
- COGT 1.2M
- Earning Date
- ORIC 08-12-2025
- COGT 08-05-2025
- Dividend Yield
- ORIC N/A
- COGT N/A
- EPS Growth
- ORIC N/A
- COGT N/A
- EPS
- ORIC N/A
- COGT N/A
- Revenue
- ORIC N/A
- COGT N/A
- Revenue This Year
- ORIC N/A
- COGT N/A
- Revenue Next Year
- ORIC N/A
- COGT N/A
- P/E Ratio
- ORIC N/A
- COGT N/A
- Revenue Growth
- ORIC N/A
- COGT N/A
- 52 Week Low
- ORIC $3.90
- COGT $3.72
- 52 Week High
- ORIC $14.67
- COGT $13.50
- Technical
- Relative Strength Index (RSI)
- ORIC 63.04
- COGT 66.38
- Support Level
- ORIC $9.87
- COGT $11.87
- Resistance Level
- ORIC $10.35
- COGT $13.50
- Average True Range (ATR)
- ORIC 0.44
- COGT 0.55
- MACD
- ORIC 0.14
- COGT 0.05
- Stochastic Oscillator
- ORIC 79.99
- COGT 77.16
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.